Flow cytometric analysis of CD132 expression on human PBMCs (human peripheral blood mononuclear cells). Human PBMCs were stained with either Biotin Mouse IgG1, κ Isotype Control (left panel) or SDT Biotin Mouse Anti-Human CD132 Antibody (right panel) at 5 μl/test followed by Sav-APC. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD132 (Common γ Chain) |
| Location | Cell membrane |
| Accession | P31785 |
| Clone Number | S-5686 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Isotype Control | S0B5431 |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD132, also known as the common cytokine receptor gamma chain (γc), is a member of the type I cytokine receptor superfamily encoded by the IL2RG gene. As a shared signaling subunit, it does not itself bind cytokines, but serves as a common component of the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, and is indispensable for signal transduction by these cytokines. Structurally, the extracellular region of CD132 contains two fibronectin type III domains, while its intracellular segment is coupled to JAK3 kinase; when a cytokine binds its specific receptor chain, JAK1 and JAK3 undergo transphosphorylation and activation, which in turn phosphorylates STAT proteins and initiates the JAK/STAT signaling pathway. CD132 is widely expressed on the surface of leukocytes, and its functional deficiency has profound clinical significance: mutations in the IL2RG gene are the most common cause of X-linked severe combined immunodeficiency (XSCID), in which patients are severely deficient in or lack functional T cells and NK cells, while B cell numbers are normal but functionally defective, resulting in severe immune dysfunction. Given its central role in signal transduction through multiple inflammatory cytokine receptors, CD132 has also become a potential therapeutic target for autoimmune diseases such as systemic lupus erythematosus, and humanized monoclonal antibodies targeting CD132 are under development.
Picture
Picture
FC
